Drug Enforcement Administration (DEA) has proposed permanent rules for prescribing controlled medications through telemedicine, which were established during the coronavirus disease 2019 pandemic. The proposed rules address telemedicine consultations by a medical practitioner who has never conducted an in-person evaluation of a patient and that would result in the prescribing of a controlled medication. Under these circumstances, a medical practitioner would be allowed to prescribe a 30-day supply of Schedule III-V nonnarcotic controlled medications or a 30-day supply of buprenorphine for the treatment of an opioid use disorder without an in-person evaluation or referral from a medical practitioner who has conducted an in-person evaluation, as long as the prescription is otherwise consistent with any applicable federal and state laws.